|   From the Trenches

Hacking the Human Cell – How Once ‘Un-druggable’ Proteins Became the New Frontier in Drug Development

White Hat Hackers, sometimes called “ethical hackers,” are individuals that work to find and fix security problems in a system by exploiting its entry points. They don’t use their computers like the rest of us do. While most of us start our workdays by firing up a laptop, clicking a web browser icon and moving through a series of user-friendly, color-coded steps, white hat hackers spend their days looking at black screens strewn with code that seems unintelligible to the untrained eye. It’s as if they are getting behind the screen, peering deep inside the inner workings of the computer where they can unlock secret functions and reprogram conventional behaviors.

By Jonathan Montagu, CEO and founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   From the Trenches

International Partnerships in Biotech: How Small Details Can Have a Big Impact

Imagine yourself setting out to do business in Japan. You step off the plane, check into your hotel, take a quick nap and then head to a restaurant to meet your potential new Japanese colleagues. You shake hands, sit down, enjoy a delicious meal, talk business – get straight to the deal – and then graciously pick up the check when it arrives at the table. It’s the beginning of a beautiful relationship.

By Deanna Petersen, CBO of AVROBIO, and Ted Tanaka, consultant with Tanaka International LLC, as part of the From The Trenches feature of LifeSciVC

Read more.


  |   In the News

A new day for pediatric cancer patients: Day One’s share price doubles on initial data for brain tumor drug

Day One Biopharmaceuticals appears to be living up to its namesake of altering pediatric cancer care from day one, unveiling positive initial data for its brain tumor drug that saw its share price double on Monday morning.

Read more.


  |   From the Trenches

Leading With Head And Heart – Navigating The Human Side Of Tough Decisions

2022 has brought unique challenges for growing companies.  Capital markets, shifting regulatory winds and other emergent forces are driving tough decisions on programs, personnel, and strategy (see discussion on framing these decisions).

By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC

Read more.


  |   From the Trenches

The Courage of Patients in Phase 1 Cancer Trials

I had the opportunity to witness true courage as I met Chrissy Harding several times before she passed away from advanced lung cancer. Diagnosed in 2016, Chrissy started her treatment journey by following conventional lung cancer regimens available at the time. When she stopped responding to standard therapy, and her cancer progressed, her doctors recommended she try a clinical trial. When she passed away in the summer of 2021, she was in her third early-stage clinical trial. Like Chrissy, many people with end-stage cancer often run out of options with approved treatments and may turn to Phase 1 clinical trials to test potential new cancer treatments. We know this decision takes tremendous courage and we are inspired by them.

By René Russo, CEO of Xilio Therapeutics, as part of the From The Trenches feature of LifeSciVC

Read more.